917 / 1631
Double and Triple Hit…
•
5% of DLBCL patients
•
Approx. 60%
BCL2
, 20%
BCL6
and 20%
triple hit
•
Limited data on
MYC/BCL6
DHL therapy
•
R-CHOP is inadequate therapy
•
Do we need to FISH all DLBCL cases?
Low prevalence
Johnson et al. Blood 2009
OS DHL BC Series